BMO Capital analyst Alex Arfaei weighed in on today's weakness in Valeant Pharmaceuticals (NYSE: VRX), saying they suspect that the ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Hedge Funds Short Sales

Valeant (VRX) Price Target Cut to $195 at Guggenheim; Thesis IntactNovember 6, 2015 6:29 AM Worst Case Valeant (VRX) is a Buy - MizuhoNovember 5, 2015 3:13 PM HedgEye says Valeant Pharma (VRX) may fall another 75%November 5, 2015 1:14 PM Three Reasons Valeant (VRX) is Plunging TodayNovember 5, 2015 12:02 PM Ackman backs Valeant CEO as shares tumble to 2-1/2 year lowsNovember 5, 2015 10:58 AM Valeant (VRX) In Free Fall as Large Holders May Finally Be Crying UncleNovember 5, 2015 10:42 AM Ackman Stocks Trade Lower on Valeant (VRX) Free-FallNovember 5, 2015 10:25 AM Valeant Pharma (VRX) Plunges Over 16%November 5, 2015 10:12 AM